Nontuberculous mycobacterial (NTM) lung disease is a chronic pulmonary infection caused by environmental bacteria that are related to, but distinct from, the bacterium that causes tuberculosis. Cases have been rising worldwide for decades, driven largely by a single group of organisms called Mycobacterium avium complex, or MAC.1PubMed Central. Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review Unlike tuberculosis, NTM lung disease is not a classic contagion you catch from a sick coworker. The bacteria live in water, soil, and household plumbing, and they tend to cause trouble in people whose lungs are already structurally or immunologically vulnerable.
Where These Bacteria Live
NTM species are ubiquitous in the natural environment. They thrive in water systems, including municipal drinking water and building plumbing.2PubMed Central. Shower water contributes viable nontuberculous mycobacteria to indoor air One of the more striking findings in recent years is the degree to which showerheads harbor these organisms. Studies have found that NTM are consistently the most abundant bacteria in residential showerhead biofilms, and that geographic “hot spots” for high showerhead NTM levels overlap with regions where NTM lung disease is most common.3PubMed Central. Ecological Analyses of Mycobacteria in Showerhead Biofilms and Their Relevance to Human Health Earlier work found that NTM concentrations in showerhead biofilms can exceed background water levels by more than a hundredfold, and that showering aerosolizes these organisms, creating a direct route to the lungs.4PubMed Central. Opportunistic pathogens enriched in showerhead biofilms
Soil is the other major reservoir. In Hawai’i, a state with notably high NTM disease rates, researchers found that NTM are most likely to be present in soils that swell when wet, hold a lot of moisture, and are rich in iron-containing minerals.5PubMed Central. Soil Properties and Moisture Synergistically Influence Nontuberculous Mycobacterial Prevalence in Natural Environments of Hawai’i Environmental factors like annual rainfall and soil mineral composition have also been linked to NTM positivity among people with cystic fibrosis in Florida.6PubMed Central. Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida The bottom line is that warm, humid climates with particular soil chemistry create ideal conditions for NTM, which helps explain the geographic clustering of disease.
Who Is Most Vulnerable
Most people breathe in NTM routinely without any consequences. The bacteria become a problem when the lungs or immune system cannot clear them effectively. Several overlapping risk factors make certain groups especially susceptible.
The most recognized patient profile is a lean, postmenopausal woman with no smoking history. Researchers sometimes call this the “Lady Windermere” phenotype, after a pattern first described in the 1990s. These patients tend to have underlying bronchiectasis, widened airways that trap mucus and create a welcoming environment for NTM. Low body mass index, impaired airway clearance, and gastroesophageal reflux disease (GERD) are all modifiable factors that contribute to NTM lung disease development.7PubMed Central. Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease
The GERD connection deserves special attention because it is both underappreciated and actionable. The prevailing theory is that acid reflux allows tiny amounts of stomach contents, potentially carrying NTM swallowed in contaminated water or food, to be aspirated into the lungs. Repeated episodes gradually damage the airway’s protective barriers, creating a foothold for infection.8CHEST. Gastroesophageal Reflux Disease Increases Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease
Cystic fibrosis is another major predisposing condition, particularly in younger patients. And even among people without a formal CF diagnosis, subtle dysfunction in the CFTR gene, the gene responsible for cystic fibrosis, may play a role. In one study of 40 NTM lung disease patients, nearly 58% had elevated sweat chloride levels (a marker of CFTR dysfunction), and clinically relevant CFTR gene variants were identified in about 29% of those tested.9Respiratory Investigation. The spectrum of CFTR dysfunction in patients with nontuberculous mycobacterial pulmonary disease This suggests there is a spectrum of CFTR-related vulnerability that extends well beyond classic cystic fibrosis.
Rare genetic immune deficiencies also matter. Defects in the signaling pathway that involves interleukin-12 and interferon-gamma, two molecules the immune system uses to fight intracellular pathogens, can lead to severe and sometimes overwhelming mycobacterial infections. When this kind of genetic susceptibility is suspected, specialized testing is available.10PubMed Central. What We Have Here Is a Failure to Communicate: Interleukin-12 / Interferon-gamma Axis Defects and Mendelian Susceptibility to Mycobacterial Disease
The Two Main Clinical Forms
NTM lung disease does not look the same in every patient. It appears in two major patterns, and the distinction matters enormously for treatment decisions.
The fibrocavitary form typically strikes older men, often smokers, and tends to be aggressive. Symptoms include productive cough, shortness of breath, coughing up blood, fever, night sweats, and weight loss. Patients with this form often have preexisting lung conditions like COPD. Cavities form in the upper lobes of the lungs, and advanced cases can lead to respiratory failure within one to two years. This form carries the highest mortality rate of any NTM lung disease pattern.11Rev. Soc. Bras. Med. Trop.. Non-tuberculous mycobacterial lung disease: a brief review focusing on radiological findings
The nodular bronchiectatic form is the slower-burning counterpart. It typically occurs in middle-aged, nonsmoking women and tends to progress over years or even decades. On CT scans, it shows up as small nodules scattered through the lungs alongside widened bronchial tubes. Because progression is so gradual, treatment guidelines allow for a cautious observation period rather than immediate drug therapy.12PubMed Central. Natural course of the nodular bronchiectatic form of Mycobacterium Avium complex lung disease: Long-term radiologic change without treatment
A third pattern, hypersensitivity pneumonitis caused by inhaling large amounts of NTM-containing aerosols, is less common but is recognized as a distinct inflammatory reaction rather than a chronic infection.13Rev. Soc. Bras. Med. Trop.. Non-tuberculous mycobacterial lung disease: a brief review focusing on radiological findings
Why Diagnosis Is Tricky
One of the most frustrating aspects of NTM lung disease is that finding NTM in a sputum sample does not necessarily mean you have the disease. NTM can be present in the airways as harmless bystanders, a situation called colonization, without actually causing infection.14PubMed. Differentiation between persistent infection/colonization and re-infection/re-colonization of Mycobacterium abscessus isolated from patients in Northeast Thailand Telling the difference between true disease and colonization is clinically important but genuinely difficult.15PubMed Central. AI-assisted differentiation of nontuberculous mycobacterial pulmonary disease from colonization: a multi-center study
Diagnosis requires meeting a combination of criteria: compatible symptoms, characteristic findings on chest imaging (nodules, bronchiectasis, or cavities), and microbiological confirmation through multiple positive sputum cultures or a positive culture from a lung biopsy or bronchoscopy sample. These criteria exist precisely because a single positive culture might just mean the person inhaled some NTM from their shower that morning. The whole diagnostic framework is designed to separate people who are genuinely infected from those whose airways are temporarily contaminated.
Which Species Matter Most
More than 150 NTM species have been identified, but only a handful cause the vast majority of lung infections. Mycobacterium avium complex is the most common culprit worldwide, followed by Mycobacterium kansasii and Mycobacterium abscessus.16PubMed Central. Nontuberculous mycobacterial pulmonary infections The species matters because treatment and prognosis differ significantly between them.
M. abscessus is particularly feared because of its intrinsic resistance to many antibiotics. It carries a gene called erm(41), which encodes an enzyme that confers resistance to macrolide antibiotics, the cornerstone drugs used against NTM. This resistance can be “switched on” by exposure to the very drugs intended to kill it, with azithromycin triggering resistance faster than clarithromycin.17PubMed Central. Dissecting erm(41)-Mediated Macrolide-Inducible Resistance in Mycobacterium abscessus This inducible resistance is a major reason M. abscessus infections are so difficult to clear, with eradication rates substantially lower than for MAC.
Standard Treatment for MAC Lung Disease
For the most common type of NTM lung disease, caused by MAC, the recommended treatment is a three-drug combination: a macrolide (either clarithromycin or azithromycin) plus rifampin plus ethambutol. This regimen should continue for at least 12 months after sputum cultures turn negative, meaning the total treatment duration often stretches to 18 months or more.18PubMed Central. Treatment of Mycobacterium avium Complex Pulmonary Disease
How well does it work? A recent study evaluating a simplified two-drug daily regimen (macrolide plus ethambutol) in 108 patients found that about two-thirds achieved culture conversion, and roughly three-quarters had a favorable overall response when clinical improvement was also counted.19Open Forum Infectious Diseases. Treatment Outcomes of Mycobacterium avium Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol Those numbers are encouraging, but they also mean roughly a quarter of patients do not respond adequately. The drugs also come with real side effects: ethambutol can affect vision, rifampin interacts with many other medications, and macrolides can cause gastrointestinal problems and hearing changes. Treatment is genuinely burdensome, and side effects are a common reason for interruptions.
When Standard Treatment Fails
For patients with refractory MAC lung disease, meaning those who don’t clear the infection after months of standard therapy, an inhaled form of the antibiotic amikacin (marketed as Arikayce) is available as add-on therapy. It is delivered via a specialized nebulizer directly to the lungs, which concentrates the drug where it is needed while reducing the systemic toxicity that intravenous amikacin can cause. In clinical trials, adding this inhaled amikacin to standard therapy significantly improved the likelihood of achieving culture conversion compared to standard therapy alone, and the benefit held at three months after stopping treatment.20PubMed Central. Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
In an open-label extension study, about a third of newly initiated patients achieved culture conversion by 12 months, while patients who had already been on treatment longer saw lower conversion rates.21PubMed Central. Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial This underscores a pattern across all NTM treatments: the longer the disease has been present and the more treatments have been tried, the harder it becomes to eradicate.
The Role of Surgery
For some patients, particularly those with localized cavitary disease or severe bronchiectasis that is not responding to drugs, surgical resection of the affected lung tissue is an option. This is not a first-line approach; it is reserved for cases where medications are failing, complications like massive hemoptysis arise, or the disease is concentrated in a region of lung that can be safely removed.
The results of surgery, when patients are carefully selected, can be impressive. In one matched comparison, about 82% of surgical patients achieved long-term negative cultures, compared with 50% in a non-surgical group.22PubMed Central. The impact of adjuvant surgical treatment of nontuberculous mycobacterial pulmonary disease on prognosis and outcome Another study of 53 patients with positive cultures at the time of surgery reported initial culture conversion in about 72%, though some of those patients later relapsed.23PubMed Central. Outcomes of adjunctive surgery for nontuberculous mycobacterial pulmonary disease
Surgery is not without risks. Complications within 90 days of discharge occurred in roughly a quarter of patients in one U.S. series. Cavitary disease, bacterial coinfections, and more extensive procedures were associated with higher odds of adverse outcomes, while minimally invasive approaches and perioperative intravenous amikacin were associated with fewer complications.24CHEST. Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States
Nonpharmacological Approaches
Drug therapy and surgery get most of the attention, but nonpharmacological management is an important complement that is often underemphasized. Airway clearance techniques, such as oscillating positive expiratory pressure devices, chest physiotherapy, and hypertonic saline nebulization, have shown positive effects in small studies.25PubMed Central. Optimising non-pharmacological interventions in people with non-tuberculous mycobacterial pulmonary disease: a systematic review These techniques help loosen and clear the mucus that NTM thrive in, which supports the effectiveness of antibiotics and may slow disease progression even in patients who are being watched without drug treatment.
Managing reflux with appropriate anti-reflux measures, maintaining adequate nutrition to counteract the low BMI that many NTM patients have, and reducing exposure to NTM-rich environments are all considered part of a comprehensive approach.26PubMed Central. Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease Some patients replace their showerheads regularly, install point-of-use water filters, and avoid activities that aerosolize soil or water. The evidence for any single environmental intervention is thin, but the biological plausibility is strong given what we know about where these organisms live.
The Toll on Daily Life and Finances
NTM lung disease is not just a medical problem; it is an endurance test. Quality of life tends to decline over time in patients with refractory disease, driven by chronic cough, fatigue, the social isolation of a poorly understood illness, and the sheer grind of prolonged antibiotic regimens.27PubMed. Assessment of health-related quality of life in patients with nontuberculous mycobacterial pulmonary disease: A comprehensive review
The financial burden is substantial too. In South Korea, which tracks these costs closely, the median cumulative cost per patient was roughly $5,000, with patients paying about half of that out of pocket. Diagnostic tests and medications accounted for about 60% of total costs.28Emerging Infectious Diseases. Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015–2019 In high-income Western countries, the costs are considerably higher. A multinational study of refractory MAC lung disease found average annual direct medical costs of about $16,200 in Canada, roughly €17,900 in France, €11,600 in Germany, and £9,700 in the UK.29PubMed Central. The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study In the United States, national hospital costs for pulmonary NTM rose significantly year over year.30PubMed Central. Hospital costs in the US for pulmonary mycobacterial diseases
NTM in Children with Cystic Fibrosis
NTM lung disease is predominantly a condition of older adults, but it also affects children, particularly those with cystic fibrosis. NTM infection prevalence in pediatric CF patients has been increasing, and it creates a uniquely challenging clinical situation.31Archives of Disease in Childhood. Treating nontuberculous mycobacteria in children with cystic fibrosis: a multicentre retrospective study
Even children under 12 can meet diagnostic criteria for NTM disease. In one review, 17 pediatric CF patients had positive mycobacterial cultures before age 12, and those who met full microbiological criteria for disease experienced greater declines in lung function over time.32PubMed. Nontuberculous mycobacterial infection in young children with cystic fibrosis Treatment in children mirrors the adult regimens in principle, requiring multiple drugs over extended periods, but the practical challenges are amplified. Side effects are frequent, and many families face the prospect of gastrostomy tubes for nutrition support and long-term intravenous access for antibiotics. The emotional and psychological toll on children and their families is significant.33PubMed. Disease caused by non-tuberculous mycobacteria in children with cystic fibrosis
Species identification matters even more in the pediatric setting. In a UK study, eradication was achieved in 80% of children with MAC infections but only 48% of those infected with M. abscessus complex, a stark gap that underscores why M. abscessus is considered the more formidable pathogen.34Archives of Disease in Childhood. Treating nontuberculous mycobacteria in children with cystic fibrosis: a multicentre retrospective study
Can NTM Spread Between People?
For a long time, the standard teaching was that NTM infections are acquired independently from the environment and do not spread person to person. That assumption has been shaken, at least for M. abscessus. A landmark study at a UK cystic fibrosis center used whole-genome sequencing to identify two clusters of patients with near-identical M. abscessus isolates, with so little genetic variation between patients that independent environmental acquisition was essentially ruled out. All patients in these clusters had overlapping hospital contact, while no environmental source within the hospital could be identified.35The Lancet. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study
Subsequent global analysis of M. abscessus isolates went further, finding that the majority of infections may be caused by recently emerged dominant clones that have spread globally, potentially through contaminated surfaces and aerosols rather than just independent environmental pickup.36PubMed Central. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium These findings transformed infection control practices at cystic fibrosis centers worldwide. Many now enforce strict separation between CF patients to minimize any chance of cross-contamination, a policy that did not exist before this genomic evidence emerged.
For MAC, the dominant NTM species overall, person-to-person transmission has not been demonstrated in the same way. The transmission concern is specific to M. abscessus, and it is most relevant in healthcare settings where vulnerable patients are concentrated. There is no evidence that healthy household contacts are at meaningful risk of catching NTM from a family member with the disease.
Rising Rates and Geographic Patterns
NTM lung disease has been increasing in most parts of the world for at least two decades. Mortality data from 83 countries confirm that nontuberculous mycobacterial-associated death rates are highest in the Western Pacific region and that older populations bear a disproportionate share of the burden.37PubMed. Trends in nontuberculous mycobacterial disease mortality based on 2000-2022 data from 83 countries The reasons for geographic variation are not fully understood but likely involve a combination of climate (warmth and humidity favor NTM growth in water and soil), water treatment practices, aging populations, and increasing use of immunosuppressive medications.
Whether the rise in NTM disease reflects a true increase in infections or better detection is debated, and the honest answer is probably both. Awareness has grown, CT scanning has become routine for unexplained coughs, and mycobacterial culture techniques have improved. But the environmental conditions that promote NTM exposure, such as warmer average temperatures and more people living with conditions that suppress immunity, are also trending in the direction of more disease. Researchers are still working to disentangle these factors, and the geographic disparities suggest that local environmental drivers deserve at least as much attention as host-level risk factors.